Please ensure Javascript is enabled for purposes of website accessibility
Adria Cimino

Adria Cimino


Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter.

Recent articles

GettyImages-two people smile as they look at a tablet

Market Dip? Here's Why This Bargain Biotech Is a Smart Buy Now

This company is a market leader -- and business is growing.

GettyImages-an investor reads something on his phone

Better Growth Stock: Novavax vs. Teladoc

They both skyrocketed early in the pandemic.


Will Cardano Hit $3 in 2022?

One big catalyst this year may help.

GettyImages-two women study something on computer

The Biggest Challenge Solana Faces in 2022

It's one of the reasons behind recent declines.


The Worst Mistake Shiba Inu Investors Can Make Right Now

The popular meme token skyrocketed last year.


Where to Invest $5,000 for the Next 5 Years

Aim for companies with solid earnings prospects.


Should You Invest in Pfizer in 2022?

This may be another big year for coronavirus program revenue.

GettyImages-three investors look at a computer_in office

1 Green Flag for Novavax in 2022, and 1 Red Flag

The company has reached the coronavirus vaccine finish line.


The Worst Mistake Moderna Investors Can Make in 2022

It's important to look at the big picture.


Shiba Inu: Buy, Sell, or Hold in 2022?

This dynamic cryptocurrency already skyrocketed last year.


3 Reasons to Buy Teladoc in 2022

Teladoc has what it takes to deliver gains over the long term.

GettyImages-woman points at computer with a pen to show something to a colleague

These Explosive Cryptocurrencies Could Beat Shiba Inu in 2022

They have plenty of momentum -- and elements that help them stand out from the crowd.


Could Novavax Go Parabolic?

The stock lost its luster last year -- but catalysts are ahead.


Could This Metaverse Crypto Be a Multibagger?

Rapper Snoop Dogg calls this place home.


Missed Out on Shiba Inu? Here's What to Buy Now

This player has a catalyst that may spark near-term and long-term gains.


Is Moderna Stock Too Expensive in 2022?

It's important to look at vaccine sales prospects -- and potential future products.


3 Cathie Wood Stocks That Could Deliver Bigger Gains Than the Market

They're all about innovation.


Should You Invest in Shiba Inu in 2022?

A catalyst may be on the way.


Novavax Stock: Buy, Sell, or Hold in 2022?

Revenue is right around the corner.


3 Cryptocurrencies That Could Dwarf Shiba Inu

They have what it takes to climb over the long term.